Clinical Insights: September 20, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ojjaara™(momelotinib) Tablets – New Drug Approval – September 15, 2023 – GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Ojjaara™(momelotinib) for the…
Clinical Insights: September 6, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Reblozyl® (luspatercept-aamt) for Injection – New Expanded Label – August 28, 2023 – Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and…
Clinical Insights: August 16, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Elrexfio™ (elranatamab-bcmm) Injection – New Drug Approval – August 14, 2023 – The Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio™, Pfizer, Inc.), a bispecific B-cell maturation antigen…
Clinical Insights: August 2, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval RiVive™ (naloxone hydrochloride) Nasal Spray – New Drug Approval – July 28, 2023 – The U.S. Food and Drug Administration approved RiVive™, 3 milligram (mg) naloxone hydrochloride nasal spray for…
Clinical Insights: July 19, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Beyfortus™ (nirsevimab-alip) Injection – New Drug Approval – July 17, 2023 – The U.S. Food and Drug Administration approved Beyfortus™ (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…
Clinical Insights: June 21, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Columvi® (glofitamab-gxbm) Injection – New Drug Approval – June 15, 2023 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and…
Clinical Insights: June 14, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Linzess® (linaclotide) Capsules – New Label Expansion – June 12, 2023 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today…
Clinical Insights: May 10, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Mydcombi™ (phenylephrine hydrochloride and tropicamide) Ophthalmic Spray – New Drug Approval – May 5, 2023 – Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for…
Clinical Insights: May 3, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lumryz™ (sodium oxybate) – formerly FT218 – New Drug Approval – May 1, 2023 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform…
Clinical Insights: April 19, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Omisirge® (omidubicel-onlv) Suspension for Infusion – New Drug Approval – April 17, 2023 – The U.S. Food and Drug Administration approved Omisirge® (omidubicel-onlv), a substantially modified allogeneic (donor) cord…
Clinical Insights: March 22, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Tafinlar® (dabrafenib) – New Label Expansion – March 16, 2023 – The Food and Drug Administration approved dabrafenib (Tafinlar®, Novartis) with trametinib (Mekinist®,…
Clinical Insights: March 8, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Skyclarys™ (omaveloxolone) Capsules – New Orphan Drug Approval – February 28, 2023 – FDA has approved Skyclarys™ (omaveloxolone) as the first treatment for Friedreich’s ataxia, a rare, inherited, degenerative…